AstraZeneca&#39;s Exanta Not Approved
691286
Drug maker AstraZeneca PLC said Friday that the Food and Drug Administration did not approve its orally taken blood thinner Exanta.
113293
AstraZeneca was dealt a blow yesterday when an official from the US&#39;s drugs watchdog questioned whether one of its key products ought to be sold in the world&#39;s largest pharmaceuticals market.
697522
If its latest drug isn't approved, the pharmaceutical could face trouble.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
106113
Shares in AstraZeneca tumbled today after a key drug it has developed in the fight against strokes was provisionally rejected by US regulators.
695798
Yet another delay from the FDA leaves investors hanging.
438801
Federal regulators said yesterday that they won&#39;t approve La Jolla Pharmaceutical&#39;s experimental lupus drug without an additional human study to prove its benefits.
45410
AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer in a major clinical trial, sending its shares down as much as 9.2 percent.
159402
AstraZeneca&#39;s recent full-page newspaper advertisements defending the safety of its cholesterol-lowering pill, Crestor, are &quot;false and misleading,&quot; in part because
564304
WASHINGTON/LONDON  - An FDA review AstraZeneca  Plc's  under the name Coumadin.
520589
Investors are discouraged after it releases the latest data for its top drug.
140812
WASHINGTON (CBS.MW) - An advisory panel to the Food and Drug Administration late Friday declined to endorse AstraZeneca&#39;s anti-stroke drug, Exanta.
115547
AstraZeneca Plc's experimental cancer  drug AZD2281 has been given orphan drug status by the European  Medicines Agency for treating women with ovarian cancer,  Britain's second biggest drugmaker said on Tuesday.
481177
Hostile environment prompts root and branch review. Exanta unlikely to win US approval in near future. By Stephen Foley. AstraZeneca, the UK&#39;s number two pharmaceuticals company, has launched a &quot;root and branch
619980
Leading London shares closed lower as drugmaker AstraZeneca suffered a heavy blow following a negative EU ruling on one of its patents.
371568
The European Union rejects Neurochem's lead drug.
638956
AstraZeneca Plc  is convinced  it can prevail in U.S. patent disputes over its two biggest  drugs, Nexium and Seroquel, and has had no discussions about  settling the cases, its chief executive said on Wednesday.